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Atrial ﬁbrillation (AF) is the most common arrhythmia and its prevalence is increas-
ing due to the progressive aging of the population. About 20% of strokes are attribut-
able to AF and AF patients are at ﬁve-fold increased risk of stroke. The mainstay of
treatment of AF is the prevention of thromboembolic complications with oral antico-
agulation therapy. Drug treatment for many years has been based on the use of vita-
min K antagonists, but recently newer and safer molecules have been introduced
(dabigatran etexilate, rivaroxaban, apixaban, and edoxaban). Despite these ad-
vances, many patients still do not receive adequate anticoagulation therapy because
of contraindications (relative and absolute) to this treatment. Over the last decade,
percutaneous closure of left atrial appendage, main site of thrombus formation dur-
ing AF, proved effective in reducing thromboembolic complications, thus offering a
valid medical treatment especially in patients at increased bleeding risk. The aim of
this consensus document is to review the main aspects of left atrial appendage oc-
clusion (selection and multidisciplinary assessment of patients, currently available
methods and devices, requirements for centres and operators, associated therapies
and follow-up modalities) having as a ground the signiﬁcant evolution of techniques
and the available relevant clinical data.
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Introduction
Non-valvular atrial fibrillation (AF) is the most common form
of cardiac arrhythmia and its incidence and prevalence are
constantly increasing1 due to the ageing of the population
and the higher survival rates of patients with conditions such
as ischaemic cardiopathy, valve defects, congenital heart de-
fects, and cardiac insufficiency. The estimated prevalence in
the general population is about 2% and increases with age.1
The lifetime risk of onset of AF is 25% inmen andwomenwith
age> 40 with heart defects, while for those without heart
defects the risk is about 15%.2,3 A diagnosis of AF features in
about 3–6% of hospitalizations for acute heart conditions,3 es-
pecially coronary heart diseases and congestive cardiac insuf-
ficiency. In the general population, arterial hypertension is
the most common condition associated with AF.3,4 Moreover,
AF is a common post-operative complication, especially after
cardiothoracic surgery.3,4 However, there are also isolated
forms of AF, diagnosedmainly by exclusion once concomitant
cardiac diseases have been ruled out.
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Most patients are asymptomatic and AF is an occasional
occurrence. In some patients, it may occur with minor
symptoms (palpitations) while in others the first onset may
be a complication of AF such as ischaemic stroke. The pres-
ence of AF is an independent risk factor for increased mor-
tality and morbidity, and is a cause of stroke and/or
thromboembolism, congestive cardiac insufficiency, and
seriously reduced quality of life, with a consequent in-
crease in health-care costs.3,4 The risk of stroke in patients
with non-valvular AF is5% per year and at least 15–20% of
all ischaemic strokes are associated with AF.5 AF is also an
independent risk factor for the recurrence of stroke6 and is
associated with higher mortality and morbidity than stroke
not correlated to AF, underlining the need for more effect-
ive stroke prevention in these patients.5,6
AF, subdivided into ‘valvular’ (patients with mechanical
valve prostheses or mitral stenosis) and ‘non valvular’, is
classified in four different categories depending on the
mode of presentation and duration of the arrhythmia:
(1) paroxystic AF (ends spontaneously or after therapy
within 7 days after onset),
(2) persistent AF (lasts more than 7 days),
(3) persistent or long-standing AF (continues for more
than 1 year), and
(4) permanent AF (continual, and the patient and phys-
ician have decided together against attempts at
cardioversion and maintenance of the sinus
rhythm).
The risk of stroke is basically the same for all four types
of AF.4
Stroke and thromboembolic risk layering:
risk of haemorrhage associated to oral
anticoagulant treatment
The presence of AF is an independent risk factor for ischae-
mic stroke and thromboembolic events, significantly in-
creases mortality and morbidity and can cause serious
disabilities, as well as longer hospitalization.
The treatment of choice for the prevention of ischaemic
stroke is oral anticoagulant therapy (OAT) with warfarin or,
in the case of non-valvular AF, with the new oral anticoagu-
lants (NOACs). In the case of non-valvular AF, warfarin has
been shown to reduce the risk of stroke by about 62%, but it
increases the risk of haemorrhage in percentages which vary
from 1.2% to 3.4% per year.7 NOACs have proved equally ef-
fective with a lower risk of cerebral haemorrhage.4
In about 90% of non-valvular AF patients, the thrombi
form in the left atrial appendage (LAA);8 however, it is fun-
damental to bear in mind that, even in AF patients, ischae-
mic stroke can be correlated to other factors, such as
hypercoagulability or atherosclerosis of the ascending
aorta and carotids.
Basically, the management of AF can be summed up in
twomain steps:
(1) identification and treatment of predisposing factors
and concomitant pathologies and
(2) assessment of the thromboembolic risk and haemor-
rhagic risk for choice of the best therapeutic
strategy.
In AF patients, risk layering is crucial. In fact, in spite of
the plentiful, universally accepted evidence of the benefits
of OAT in reducing the risk of ischaemic stroke, many stud-
ies have revealed that this therapy is underused, especially
in high-risk patients.8,9 A large number of stroke risk layer-
ingmethods have been produced on the basis of risk factors
identified in the control arms of clinical studies on war-
farin, cohort studies and consent documents. These meth-
ods vary in complexity and the number of risk factors
assessed, but they have almost all divided AF patients, by
convention, into low, moderate and high risk.4,10
CHA2DS2-VASc
10 is the thromboembolic risk assessment
score recommended by the European Society of Cardiology
(ESC), the American Heart Association (AHA) and the
American College of Cardiology (ACC), which considers
gender, vascular diseases, cardiac insufficiency, hyperten-
sion, age (divided into two classes), diabetes and ischaemic
stroke as risk factors.
The HAS-BLED score is the most widely used for the
layering of haemorrhage risk.11 HAS-BLED has been com-
pared with the HEMORR2HAGES method and with ATRIA
and, although, like the others, it has shown only a moder-
ate ability to predict the risk of bleeding, it has proved the
most effective in significantly predicting the risk of intra-
cranial haemorrhage, and is also the simplest.12 A HAS-
BLED score 3 identifies patients with high risk of haemor-
rhage but is not a criterion for exclusion from OAT.
Tables 1 and 2 summarize the risk factors assessed in
CHA2DS2-VASc and HAS-BLEDwith the relative scores.
The final decision on the type of antithrombotic treat-
ment in AF patients must therefore balance the degree of
reduction of the risk of thromboembolism against the mini-
mization of serious haemorrhagic complications (in other
words intracranial haemorrhage) associated with these
therapies.
Current antithrombotic treatment
recommendations
An analysis of the net clinical benefit (balancing the reduc-
tion of ischaemic and haemorrhagic events) of vitamin K
antagonists was conducted on a large population of AF pa-
tients in the real world (n¼ 130 000) using the CHA2DS2-
VASc and HAS-BLED scores. This study revealed a net bene-
fit for anticoagulant therapy in patients with CHA2DS2-
VASc2. The effect was neutral in patients with CHA2DS2-
VASc¼1, while there was no net benefit in patients with
CHA2DS2-VASc¼0. Moreover, this study further confirmed
the absence of benefits from aspirin alone in any risk
layer.13,14
The most recent guidelines (2014) on the treatment of
AF are those of the AHA/ACC,15 which suggest, in AF pa-
tients with CHA2DS2-VASc2, the use of warfarin with class
I and level of evidence A and of NOACs with class I and level
of evidence B, while the 2012 ESC guidelines16 recommend
class I with level of evidence A for both warfarin and NOACs
in the same patients. In patients with CHA2DS2-VASc¼1,
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the US guidelines basically advise against antithrombotic
therapy (IIb, C), while the European ones are more in fa-
vour (IIa, A). All guidelines advise against any anticoagulant
therapy in patients with CHA2DS2-VASc¼0.
Warfarin or NOACs are definitely the most widely used
therapy with the highest level of evidence in the preven-
tion of AF-related thromboembolism. NOACs, in particular,
have been shown to be as effective as warfarin [in patients
with international normalized ratio (INR) on target], and
are associated with a lower risk of haemorrhagic events.17
Although OAT with warfarin has been shown to signifi-
cantly reduce the incidence of AF-related stroke, a high
percentage of patients with AF (40%) do not receive ap-
propriate prophylactic therapy.18,19 Moreover, about 20%
of patients have contraindications for OAT and a further
30–40% of patients receiving OAT are unable to maintain a
TTR of65%, meaning that the risk of inefficacy of the
therapy is high. Furthermore, a considerable proportion of
patients suspend anticoagulant treatment within 1 year.20
In addition, although NOACs are more manageable and ap-
parently safer than warfarin, they are still associated with
a risk of haemorrhagic events (1.6–3.6% haemorrhagic
events/year). Moreover, in the trials which tested these
new drugs, between 20% and 35% of patients were forced
to suspend administration due to the onset of side effects,
and a high risk of bleeding was one of the exclusion criteria
in all trials.
Specific clinical situations associated to high
risk of haemorrhage
The decision with regards to any antithrombotic treatment
must necessarily involve an assessment of the risk of stroke
as against the risk of major bleeding, especially cerebral
haemorrhage, which is the most dangerous complication,
associated with a high rate of mortality and disability.21
However, the risk of cerebral haemorrhage in AF patients
receiving OATwith vitamin K antagonists is currently quite
low, between 0.1% and 0.6%. The percentage of intracra-
nial haemorrhages increases for INR values around 3.5–4.0,
while there is no difference in haemorrhage risk in patients
with INR between 2.0 and 3.0 compared to those with
lower INR.21
In the general population of AF patients, there are some
categories with particularly high risk of haemorrhage,
specifically:
(1) elderly patients: it is known that the prevalence of
AF is dramatically higher in patients with age> 75
years and that in these patients the risk of
thromboembolism and haemorrhage is often much
higher than in younger patients;
(2) patients with a history of major bleeding episodes,
especially intracranial;
(3) patients with gastrointestinal diseases (liver dis-
eases, angiodysplasias) or with peptic ulcer, a con-
dition which is a significant problem for the use of
NOACs, which are associated with a higher number
of gastrointestinal haemorrhages than warfarin16–18;
(4) patients with chronic renal failure, who account for
about 3% of AF patients; in 90% of cases, this popu-
lation of patients with kidney disease has a
CHA2DS2-VASc >2 and has a HAS-BLED 3 in 40% of
cases.16–18 Moreover, there is no concrete proof on
the efficacy-safety ratio of anticoagulants in pa-
tients undergoing dialysis or with glomerular filtra-
tion rate <30mL/min.22 In dialysis patients, the
risk of ischaemic stroke is higher than that of the
general population, even in the absence of AF,23 as
is the risk of haemorrhage.24 Moreover, in haemodi-
alysis patients an association has been suggested
between the use of warfarin and an increase in vas-
cular calcification25–27;
(5) patients with coagulation disorders;
(6) patients with acute coronary diseases who have
received stent implants and require prolonged dual
Table 2 HAS-BLED score
Letter Clinical characteristics Score
H Hypertension 1
A Impaired kidney or liver function
(1 point each)
1 or 2
S Stroke 1
B Bleeding 1
L Labile INR 1
E Old age (>65 years) 1
D Drugs or alcohol (1 point each) 1 or 2
INR, international normalized ratio.
Table 1 CHA2DS2-VASc score and incidence of stroke
Risk factors for stroke and thromboembolism in non-valvular
AF
‘Major’ risk factors ‘Significant’ risk factors
Previous stroke, TIA or
systemic embolism
Cardiac insufﬁciency or
moderate or severe
systolic dysfunction
(EF< 40%)
Age> 75 years Arterial hypertension,
diabetes mellitus, female
gender, age 65–74 years,
peripheral vascular disease
Risk factors included
in the CHA2DS2-VASc score
Risk factors Score
Cardiac insufﬁciency/
systolic dysfunction
1
Arterial hypertension 1
Age 65–74 years. 1
Age> 75 years 2
Diabetes mellitus 1
Stroke/TIA/thromboembolism 2
Peripheral vascular disease 1
Female gender 1
EF, ejection fraction; TIA, transient ischaemic attack.
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antiplatelet therapy (DAPT). AF may, for example,
occur in 5–10% of patients with acute coronary syn-
drome and is associated with a significant increase in
mortality.20 In view of the fact that the vast majority
of patients with acute coronary syndrome undergo cor-
onary angioplasty with stent implant, the population
of patients requiring DAPTþanticoagulant therapy
(triple therapy) is presumably very large. It is known
and also logical that the combination of antiplatelet
agents with anticoagulants increases the risk of bleed-
ing in the case of both warfarin and NOACs. In the
Randomized Evaluation of Long-Term Anticoagulation
Therapy (RE-LY) study, the risk of major bleeding
increased by 2.8% to 4.8% per year when antiplatelet
agents were added to warfarin and from 2.6% to 4.4%/
year with dabigatran 150mg18; and
(7) patients with mental disabilities or at risk of
frequent falls.
All these categories represent a large segment of pa-
tients for whom randomized trials fail to provide clear evi-
dence with regard to the best therapeutic strategy.
Anatomy of the left atrial appendage
The LAA is an embryonic remnant of the primordial left
atrium, a small offshoot opening off the side wall of the
atrium, with variable, elongated, trabecular, often multi-
lobed shape. The appendage’s orifice on the atrial cavity is
oval in form and is located between the left upper pulmon-
ary vein, from which it is separated by the fibrous ligament
of Marshall, and the mitral valve. On the outside the LAA
extends antero-laterally parallel with the left atrioven-
tricular sulcus, just above the proximal part of the circum-
flex artery. On the inside, the distal part is trabecular, with
the distinctive uneven surface of the endocardium, while
the proximal end has a smooth surface. It varies in length
(16–51mm), volume (0.7–19.2mL) and orifice diameter (5–
40mm).28
The LAA consists of a main body onto which one or more
lobes may be attached and its variable in both shape and
size. The study performed by Di Biase et al.,29 using com-
puted tomography and magnetic resonance, gathered in-
formation about the morphology of the LAA and also
correlated the various forms with risk of ischaemic stroke/
transient ischaemic attack (TIA). Four main forms
emerged: Cactus (30%), Chicken Wing (48%), Windsock
(19%), and Cauliflower (3%). The correlation with thrombo-
embolic events revealed a diverse, significant (P< 0.001)
distribution, of 12, 4, 10, and 18%, respectively, in patients
with Cactus, Chicken Wing, Windsock, and Cauliflower
morphology. The Chicken Wing morphology showed a sig-
nificantly lower prevalence of events compared with the
other morphologies; in particular, patients with Cactus
morphology showed a risk of cerebral ischaemic events 4
times higher, those with Windsock morphology 4.5 times
higher and those with Cauliflower morphology 8 times
higher than patients with ChickenWing morphology.
Surgical closure (occlusion) of the left atrial
appendage
Surgical closure of the LAA has been proposed since the
’40s as prophylaxis for thromboembolism in patients with
mitral valve disease.30–32 Even then, the observation that
in this condition about 50% of thrombi were located in the
LAA pointed to its occlusion as prophylaxis for the risk of
stroke.33 During the same period, Belcher and Somerville32
noted that after mitral surgery LAA thrombosis occurred in
64% of patients who experienced embolic events. In the
’80s, further to the findings of a review of the mitral com-
missurotomy procedure, Halseth et al.34 suggested that
surgical occlusion was only indicated in cases of large-sized
LAA.
In modern times, LAA amputation has been reintroduced
as an integral part of the surgical procedure for AF abla-
tion, initially proposed by Cox35 in the ’90s and still per-
formed with various technologies.
The history of the surgical treatment of the LAA origi-
nated in 1949, when Madden31 performed a complete am-
putation of the LAA on 2 patients with rheumatic mitral
disease. An analysis of the literature only reveals 7 studies
with detailed assessments (Table 3).36–43 These 7 studies
recruited a total of 3653 patients with an LAA occlusion
group (LAAO) (1716 patients) compared to a non LAAO
group (1937 patients). In three works,37,39,42 the main op-
eration was mitral valve surgery, in one39 it was coronary
surgery and in the other three40,41,43 there was a mix of
aortocoronary bypass and valve procedures. Four studies
used surgical sutures for the LAAO37,38,41,42 while in two
the LAAwas amputated with a Stapler.38,43
Results
The incidence of stroke was significantly reduced in pa-
tients who underwent LAAO. Mortality was significantly
lower in the LAAO group. No significant differences were
identified between the two groups with regards to peripro-
cedural bleeding requiring reoperation.
The Left Atrial Appendage Occlusion Study (LAAOS)38 is
the first randomized trial to assess the feasibility, safety,
and efficacy of LAAO during elective coronary surgery using
surgical sutures or automatic staplers. The study, con-
ducted in Germany during 2001–2002, considers 52 patients
who underwent LAAO vs. 25 non-LAAO patients. Occlusion
was found to be effective in 66% of patients and it was even
more so when the surgeon performed a complete amputa-
tion of the LAA rather than simply suturing it; the studies
analysed reveal the uncertainty concerning the efficacy of
surgical suturing in LAAO.
Echocardiogram assessment
Imaging plays a fundamental role in both the pre- and the
intraprocedural phase, and in the follow-up.44 The LAA can
occasionally be viewed by transthoracic echocardiography,
but the transoesophageal method (TEE), sometimes with
three-dimensional assessment, is always necessary.
TEE plays a fundamental role in the pre-procedural as-
sessment, to confirm that the LAA is free from thrombi;
any thrombi must be carefully considered to ensure that
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the procedure is safe and free from complications. It also
allows the acquisition of additional information concerning
the size, shape and position of the LAA. At the end of the
surgical procedure, TEE is fundamental for defining the
positioning of the device and the achievement of LAAO, by
checking for any leaks. During follow-up, TEE is the most
accurate assessment method for the description of any
leaks or thrombosis.
TEE is the gold standard for confirming the failure of
LAAO; in this case the patient continues to be exposed to
the risk of thromboembolism, with an increased risk of
stroke.45,46 In fact, incomplete occlusion of the LAA has
been reported in up to over 50% of cases, with thrombi re-
corded in up to more than 25% of these patients.46
Furthermore, thromboembolic events have been reported
in up to 22% of these cases.47
A variety of surgical techniques are currently used in
LAAO: surgical removal, surgical suture, and more recently
the application of specific devices (Tiger Paw and Atriclip).
Surgical removal of the LAA generally involves tangential
clamping as close as possible to the orifice. It is then
removed and the orifice is sealed with a double surgical su-
ture. Since the LAA is an extremely fragile structure, this
technique may lead to tearing at its orifice, with bleeding
and difficulties in achieving haemostasis. This technique is
therefore not widely used, although in the literature no in-
crease in morbidity arising from the surgical operation is
described.38
Occlusion of the LAA by means of surgical suture is cur-
rently the most commonly used technique. Especially dur-
ing mitral valve surgery, it is a simple, quick procedure
with no complications. The surgical suture can be created
with a tobacco-pouch shape around the orifice, or by
means of two seams at its point of origin. During the last
few years, the data in the literature indicate that the use
of dedicated devices has been introduced. The devices cur-
rently available remain epicardial and therefore are not
fitted into the cavity, and they potentially have a low inci-
dence of thrombosis, infections and embolization.43
The Tiger Paw System II (Maquet Cardiovascular,
Mahwah, NJ, USA) is currently not available on the market
because of a suspicion that it may apply traction to the
atrial tissues. The Atriclip LAA Occlusion System device
(Atricure, Inc, West Chester, OH, USA) allows easy, safe
LAAO. It has been approved by the Food and Drug
Administration since 2009 and consists of a convenient
handle with the device at one end; the latter comprises a
self-clamping clip consisting of two parallel crossbars in ti-
tanium with etinol, with a polyester cladding; during the
operation the system can be positioned several times prior
to deployment, and it comes in different sizes for selection
in relation to the dimensions of the orifice of the LAA. It is a
simple, safe procedure with minimal complications and
allows complete occlusion of the LAA. It is an epicardial
and therefore not an intracavitary device, usable for all
the various shapes and sizes of LAA, and it allows anatom-
ical and electric LAAOwith short procedural times. This de-
vice is currently used in a large number of patients who
undergo mini-invasive surgery or mini-invasive surgical
treatment for AF.
Indications for surgical occlusion of the left atrial
appendage
The ESC guidelines maintain that there is no conclusive evi-
dence concerning the efficacy of LAAO or the best tech-
niques for its performance and provide a recommendation
of IIB, evidence level C, only for patients who are to
undergo cardiac surgery.17 Nor have the recent AHA/ACC
guidelines16 on the management of AF arrived at a clear
consensus on this procedure, and they confirm this recom-
mendation with the same level of evidence.
The panel agreeswith these recommendations andmain-
tains that every candidate must be discussed by the Heart
Team. Potential candidatesmay be:
(1) patients with high thromboembolic risk with per-
manent, persistent or paroxystic AF undergoing
concomitant cardiac surgery, possibly in association
with surgical ablation of the AF and
(2) patients with high-thromboembolic risk undergoing
mini-invasive surgery (mini-thoracotomy) or a ster-
notomy surgical procedure for AF.
Requirements for staff and centres
In-depth knowledge of cardiac anatomy, especially of the
left atrium, the LAA, and the surrounding structures, is es-
sential for staff performing LAAO. Staff must have in-depth
knowledge of the anatomical variables of the LAA in terms
of size, angles and mobility. The procedure’s success and
safety depend to a large extent on the knowledge and
Table 3 Studies in the literature which assessed surgical treatment of the left atrial appendage
Author Period Type of study Number
of LAA
Number of
non-LAA
LAA occlusion method
Lee et al.39 1999–2011 Propensity-score matched 119 119 LAA amputation during crio-Maze
Whitlock et al.43 2009–2010 Miscellaneous 26 25 Amputation and stapler
Kim et al.40 2001–2010 Propensity-score matched 631 631 Amputation or closure of LAA
Zapolanski et al.41 2005–2012 Observational 808 969 Double ligature with suture
Nagpal et al.37 2007 RCT 22 21 Amputation, suture
Healey et al.38 2001–2002 RCT 52 25 Suture or stapler
Garcia-Fernandez et al.42 1996–2001 Observational 58 147 Ligature of LAA with endocardial suture
LAA, left atrial appendage; RCT, randomized controlled trial.
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experience of every member of the team, including the
echocardiographer.
Specific, properly organized training is necessary for
every staff member, including the echocardiographer. The
trainingmust include basic principles and study of the char-
acteristics of the device and the procedure. It must com-
prise a short course on anatomy, clinical procedures and
device implantation techniques and the analysis of critical
factors such as patient and device selection and the pos-
sible complications and their prevention and management,
as well as a practical part and the use of simulators on vir-
tual cases. The nurses and technicians on the team must
also receive training. During the first few procedures, a
surgeon with documented experience in use of the device
must be present.44
Percutaneous occlusion of the left atrial
appendage
Left atrial appendage occlusion devices
currently available
There are currently four endocardial devices with CE mark-
ing available for percutaneous occlusion of the LAA: the
Watchman (Boston Scientific, Maple Grove, MN, USA), the
Amplatzer Cardiac Plug and Amulet (St. Jude Medical,
Minneapolis, MN, USA), the WaveCrest (Coherex Medical,
Salt Lake City, UT, USA) and the Lariat (SentreHEART, Inc.,
Palo Alto, CA, USA), which has a combined endocardial/
epicardial percutaneous access.
The Watchman is a self-expandable device with a
basket-like structure in nitinol clad with a polyethylene
membrane covering the exposed surface in the left atrium;
it has hooks around its external perimeter which anchor it
to the walls of the LAA. The device is available in various
sizes (21, 24, 27, 30, and 33mm) and is deployed with the
aid of a delivery catheter of 14 Fr which may have one or
two bends at its distal end for easier approach to the LAA.
The device’s length is equal to its diameter (Figure 1).
As of today, clinical studies conducted with the
Watchman medical device have included more than 2400
patients with more than 6000 patient years of follow-up.
The most important clinical studies supporting the efficacy
and safety of this device are the Watchman Left Atrial
System for Embolic Protection in Patients With Atrial
Fibrillation (PROTECTAF)48–50 and Prospective Randomized
Evaluation of the Watchman LAA Closure Device In Patients
With Atrial Fibrillation Versus Long Term Warfarin Therapy
(PREVAIL)51 randomized studies. In the PROTECT AF
randomized study, Holmes et al.48 compared implantation
of the Watchman with conventional pharmacological treat-
ment with warfarin in 707 patients with non-valvular AF
and CHADS2 score 1. The device was successfully im-
planted in 90.9% of the patients who underwent the pro-
cedure and the administration of warfarin was stopped in
87% of them 45 days later. The primary endpoint for effi-
cacy was defined as the composite of stroke, cardiovascu-
lar or unexplained death, and systemic embolism. The rate
of events recorded for effectiveness was 3.0 per 100 pa-
tient years in theWatchman group compared to 4.9 per 100
patient years in the warfarin group; this 38% reduction is
equivalent to a non-inferiority of the Watchman in relation
to warfarin. However, ischaemic stroke was more frequent
in the group treated with theWatchman than in the control
group due to five pre-procedural events linked to gaseous
embolism. Excluding these events, the incidence of ischae-
mic stroke was not substantially different between the two
groups (1.3%/year in the successfully implanted group
compared to 1.6%/year in the control group). The primary
endpoint for safety, on the other hand, was defined as a
composite of major bleeding and complications correlated
to the procedure. The rate of these adverse events was 7.4
per 100 patient years in the Watchman group compared to
4.4 per 100 patient years in the warfarin group. The com-
plications which occurred in the patients treated with the
Watchman were: cardiac tamponade (5%), major haemor-
rhages (3.5%), pericardial effusions (1.7%), periprocedural
stroke (1%) mainly arising from gaseous embolism, embol-
ization of the device (0.6%), which in most cases (67%)
made surgical removal necessary, and the induction of ar-
rhythmias (0.2%). In total, 2.2% of attempts to implant the
device led to cardiac surgery to deal with complications
correlated to it. Most of these events occurred in the peri-
procedural period (55% of adverse events relate to the day
of implantation) and pericardial effusion was the most
common event (7.1% of the first 3 patients at each centre
and 4.4% of subsequent patients); none of these events
caused permanent disability or death. In fact, it should be
emphasized that the adverse events correlated to the pro-
cedure decreased as the staff’s experience grew. In par-
ticular, pericardial effusions, which accounted for about
50% of adverse events recorded in the PROTECT AF study,
decreased significantly in the subsequent CAP registry as
the operators’ experience increased (5 vs. 2.2%,
P¼ 0.019), as did periprocedural strokes (0.9 vs. 0%;
P¼ 0.039).48,49
The PREVAIL study enrolled 407 patients with the aim of
comparing the Watchman device with warfarin patients
with AF at high risk of thromboembolism (average CHADS2
score of 2.6) and eligible for long-term therapy with war-
farin. The implantation success rate was 95.1%, a higher
value than reported in the previous PROTECT AF
randomized study (90.9%). In this study, LAAO with the
Watchman proved to be not inferior to warfarin in the pre-
vention of ischaemic stroke or peripheral embolism 1 week
after the procedure. Although statistical non-inferiority
Figure 1 Watchman Device (Boston Scientiﬁc).
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was not achieved for the total efficacy of the procedure,
including periprocedural events, it should be kept in mind
that the incidence of these events was low and similar in
the two arms of the study.
With regards to adverse events correlated to the proced-
ure (within 7 days), an event was reported in 2.2% of im-
planted patients. Major complications correlated to the
device or the procedure within 7 days of implantation
occurred in 4.4% of patients compared to the 8.7% of the
PROTECTAF study, meaning a 49% reduction. Pericardial ef-
fusion occurred in 1.9% of patients compared to 4.0% in
PROTECTAF, and thus with a reduction of 52%. It is import-
ant to underline that the results of the PREVAIL study re-
vealed very low-complication rates amongst both clinicians
who were performing their first implantations and more
skilled clinicians. The data relating to the use of this device
in patients with contraindications for OAT are rather lim-
ited. Specifically, in the ASAP study52 LAAO was performed
in 150 patients: the rate of cerebral ischaemic events
observed was 2.3%/year, meaning a risk reduction calcu-
lated as 77% in a population of patients with an expected
rate of events per year of 7.3%.
A meta-study including 2406 patients recruited to
PROTECTAF, PREVAIL, and the respective registries has re-
cently been published.53 Compared to warfarin therapy,
percutaneous occlusion of the LAA was associated with a
significant reduction of haemorrhagic stroke [0.15 vs. 0.96
events/100 patient years, hazard ratio (HR) 0.22,
P¼ 0.004], cardiovascular or undefined mortality (1.1 vs.
2.3 events/patient year, HR 0.48, P¼ 0.006) and non-
procedural bleeding (6 vs. 11.3 events/100 patient years,
HR 0.51, P¼ 0.006).53
The Amplatzer Cardiac Plug (ACP) is a self-expanding nit-
inol device, clad completely in polyester, in three parts: a
nitinol cylinder, called the lobe, at the tip, used to anchor
the device inside the LAA, a larger disc below it which cov-
ers and blocks the orifice of the LAA, and a very short wire
in the middle connecting the lobe and disc (Figure 2).
There are anchor hooks around the edge of the lobe. The
lobe sizes available are 16, 18, 20, 22, 24, 26, 28, and
30mm, while the disc is 4mm larger for the sizes from 16
to 22 m and 6mm larger for the 24 to 30mm sizes. The
lobe’s length is much less than its diameter, making it pref-
erable for particularly shallow LAAs. The only data avail-
able for the ACP are provided by feasibility reports
covering only small patient populations. A retrospective
registry study on a population of 137 patients in which an
attempt at occluding the LAA with ACP was performed54
show that the procedure was successful in 96% of cases;
major intraprocedural complications were observed in 7%
of cases (3 ictus, 2 device embolizations, and 5 cardiac
tamponades). The percentage rose if minor complications,
including four negligible pericardial effusions and transient
myocardial ischaemia caused by gaseous embolism, were
also considered. In another study conducted on 20 pa-
tients, the ACP was successfully implanted in 95% of cases
with 2 periprocedural complications (one transient myo-
cardial ischaemia caused by gaseous embolism and one oe-
sophageal lesion due to the TEE). In this study, no adverse
events such as stroke or death were observed during a
follow-up of 12.76 3.1 months, compared to a theoretical
risk of ischaemic events of 5.3%.55
The first Italian registry study, including a population of
134 patients with high-cardioembolic risk (average
CHA2DS2-VASc 4.36 1.3) with contraindication to the ad-
ministration of anticoagulant therapy) was published in
2014. The authors report a high-procedural success rate
(95.5%) and a low rate of major complications (2.2%). In
the follow-up, a reduction in cerebral ischaemic events of
85.5% compared to the risk predicted by the scores was
described.56 Recently, Tzikas et al.57 published the data of
a multicentric registry study which describes, on a total of
1047 patients, a procedural success rate of 97.3%, and an
incidence of procedural complications of 5%, with a 59% re-
duction in embolic events and a 60% decrease in haemor-
rhagic events calculated in relation to the CHA2DS2-VASc
and HAS-BLED scores.
Another registry study, performed on the Iberian
Peninsula, collected the data of 167 patients with contra-
indication for OATand indicated a procedural success rate of
94.6% with an incidence of procedure-related complications
of 5.38%. The incidence of embolic events was lower than
that predicted by the CHA2DS2-VASc score (2.4 vs. 8.3%), and
the incidence of haemorrhagic events was also below the
prediction provided by the HAS-BLED score (3.1 vs. 6.6%).58
The latest version of this device is the Amulet, which has
the same three-part structure as the ACP but a wider range
of sizes (16, 18, 20, 22, 25, 28, 31, and 34mm), allowing
the treatment of a wider spectrum of anatomies, a longer
lobe with more anchor hooks, a longer central wire and a
screw fitting for the disc, which has been retracted to cre-
ate a uniform surface (Figure 3).
The WaveCrest, not currently available on the market, is a
self-expanding device in nitinol with a polytetrafluoroethyl-
ene coating on the surface which remains exposed in the left
atrium; it has anchor hooks around its circumference, which
engage with the walls of the left atrium appendage. This de-
vice is designed to be positioned close to the orifice of the
left atrium appendage, with no need to penetrate deep
downwith the deployment system (Figure 4).
At present, data from feasibility and safety trials59 are
available, but there are nomajor clinical studies.
Figure 2 Amplatzer Cardiac Plug (St. Jude Medical).
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The Lariat, not currently available in Italy, is an occlusion
system with a combined approach consisting of three com-
ponents: a balloon, a guide wire with magnetic tip and a
loop suture wire which will be closed on the orifice of the
LAA (Figure 5).
The system requires the collimation of two magnets at
the tips of the first two components (used with percutan-
eous and epicardial approach), which form a single body
that serves as guide for the third component, the lariat,
positioned with epicardial approach to occlude the orifice
of the LAA. The benefit of this procedure is that once it has
been performed nothing prosthetic is left inside the left
atrium, and therefore no anticoagulant or antiplatelet
therapy is required. However, the only studies performed
on this device so far are feasibility studies on small popula-
tions of patients.
The results of a study on LAAO on 89 patients using this
device revealed that the LAA was completely occluded in
91% of cases with 3 acute complications (2 during pericar-
dial access and 1 during transseptal catheterization). After
the procedure 2 cases of pericarditis, 1 delayed pericardial
effusion, 2 sudden deaths from undetermined causes, and
2 strokes considered not to be of cardioembolic origin were
observed.60
Devices currently under development
The Watchman FLX device, (Boston Scientific) a develop-
ment on the Watchman device already described, will ap-
parently soon be available. It differs from the previous
version in shorter length, the presence of a fluoroscopic
marker on the distal tip, the possibility of recapture and re-
deployment, a larger range of sizes (20, 24, 27, 31, and
35mm) allowing treatment of a wider range of anatomies,
a larger number of perimeter anchors arranged in two rows
and retraction of the device’s screw connection, to create
a flat surface on the atrial side (Figure 6).
The Transcatheter Patch (Custom Medical Devices,
Athens, Greece) is a device consisting of a polyurethane
patch with an adhesive band at the distal end which is car-
ried into the LAA by a balloon; the proximal side of the
patch is tightened with a loop, and is then released once
the balloon has been deflated and the insertion catheter
has beenwithdrawn (Figure 7).
This device is currently undergoing clinical assessment.
Lifetech (LambreTM, Lifetech Scientific Corp.,
Shenzhen, China) is a self-expanding nitinol device
Figure 4 WaveCrest Device (Coherex Medical).
Figure 5 Lariat (SentreHEART) system with its three components.
Figure 3 Amulet Device (St. Jude Medical).
Figure 6 Watchman FLX Device (Boston Scientiﬁc).
Figure 7 Lariat (SentreHEART) system with its three components.
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consisting of three parts: a disc and an umbrella, con-
nected by a very short central component. This device is
undergoing preclinical assessment.
Cost-effectiveness studies
A number of cost-effectiveness studies have been per-
formed in different social and health-care contexts. An
analysis of the German health system, which compared
costs and outcomes in terms of mortality of the LAAO pro-
cedure compared to warfarin and dabigatran, reveals long-
term medical and financial benefits in favour of LAAO. In
fact, after 8 years LAAO is less expensive than dabigatran
(e15,061 vs. e16,184) and at 10 years it only costs 10%
more than warfarin (e16,736 vs. e15,168). The assumption
is therefore that LAAO may be financially beneficial for the
health system over the long term.61
Another study, based on costs and the years of quality-
adjusted life (QALY) gained by percutaneous occlusion of
the LAA compared to warfarin and dabigatran therapy, re-
veals that the cost per QALYof medical therapy is $46 560,
while for this device this value is $41 565 over a lifetime
period.62
From the point of view of the Italian National Health
Service, the comparison between LAAO and treatment
with a single antiplatelet drug or no drug in patients with
contraindications for OAT is in favour of occlusion of the
LAA with a benefit which comes into effect at 3 years, due
to the increase in the cost of stroke-related disability in pa-
tients treated with antiplateletmedication.63
A comparison between the costs of treatment with the
Watchman and with the NOAC drugs by the United Kingdom
Department of Health also found in favour of LAAO in pa-
tients with high risk of embolism with contraindications for
OAT: an investigation of the cost of 10 patients reveals that
the cost of the device (e49 300) is recouped within 3 years,
considering that the cost per annum of the untreated pa-
tients would amount to e14 600 (1 stroke prevented per
year for every 10 patients).64
The cost-effectiveness studies therefore reveal the po-
tential benefit of LAAO compared to anticoagulant therapy
in the long term. This benefit apparently also occurs in the
short-medium term for populations with high risk of embol-
ism and haemorrhage.
Indications for left atrial appendage
occlusion
According to the current indications for percutaneous
LAAO, which reflect the ESC guidelines,17 the procedure is
indicated (recommendation class IIb, level of evidence B)
in patients with non-valvular AF with high-thromboembolic
risk (CHA2DS2-VASc score 2) with long-term contraindica-
tion for OAT (e.g. history of intracranial bleeding, life-
threatening bleeding, coagulation diseases).
The recent EHRA/EAPCI44 consensus suggests that the
spectrum of patients who could benefit from this technique
should be extended (Table 4). Moreover, this therapy could
also be considered in the following clinical situations:
• patients with non-valvular AF with high-thromboembolic
risk and high-haemorrhagic risk (HAS-BLED 3);
• patients requiring triple antithrombotic therapy
indefinitely;
• patients with tumours with increased risk of haemor-
rhage, underestimated by the HAS-BLED score;
• patients in whom OAT is ineffective in providing protec-
tion against cerebral ischaemic events probably corre-
lated to thromboembolisms originating from the LAA;
• patients with kidney failure or undergoing dialysis,
bearing in mind that all NOACs are contraindicated
with creatinine clearance< 15mL/min and that in
these patients warfarin could increase tissue calcifica-
tion and the degree of atherosclerosis;
• patients with major bleeding of the urogenital or
gastrointestinal system, or any other districts, such as
the ocular area;
• frail patients (the very old, dementia, neurodegenera-
tive diseases, malnutrition, etc.);
• patients with difficulty in managing oral therapies
(e.g. mental illnesses, vision impairment); and
• patients who, after being suitably informed about the
OAT/NOACs therapy, refuse it and demand a ‘defini-
tive’ therapy. In this context, it should be underlined
that the Watchman has had approval by the US regula-
tory authority as a valid alternative to warfarin in pa-
tients who refuse or prefer not to take OAT.
The decision must therefore be made in the context of
the doctor–patient relationship, after appropriate informa-
tion about all the benefits and drawbacks related to the
percutaneous LAAO procedure or the alternative OAT/
NOACs therapies (Figure 8). It should however be under-
lined that at present there is no evidence on this question
and additional clinical studies are required to assess the
usefulness of LAAO in these clinical situations before the in-
dications for this type of treatment are extended to the
aforesaid groups of patients.
Screening of patients who are possible
candidates for left atrial appendage
occlusion
Screening must be carried out in the context of discussion
and choice of a strategy in agreement with the patient, giv-
ing due consideration to personal preferences and health
Table 4 Left atrial appendage occlusion: possible clinical
situations
As an alternative to OAT in patients intolerant of OAT
Patients with high risk of stroke and high risk of haemorrhage
Patients with thromboembolic events during OAT in the
therapeutic range or during treatment with NOACs (when
no other origin of the bleeding can be identiﬁed)
Patients who can be treated with oral anticoagulants but
may have indication for left atrial appendage occlusion
NOACs, new oral anticoagulants; OAT, oral anticoagulant therapy.
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expectations65 and avoiding superfluous tests or
investigations.
Screeningmust aim to establish the individual risk/bene-
fit profile and in particular the ratio between embolic and
haemorrhagic risk and its progression over time, and in-
clude the anatomical characteristics of the LAA in order to
allow planning of themost important procedural aspects.
As has been shown to be the case in cardiac surgery, with
large benefits for outcomes,66 screening must be disciplin-
ary and preferably use local protocols which clearly iden-
tify the role of each player within the team, and ensure
strong interaction between its members and the patient.67
Assessment of the patient’s preferences and health and
quality of life factors must include clear, appropriatemeth-
ods for their formal expression.68
Table 5 summarizes the main factors to be considered in
this phase of the diagnostic and therapeutic process. From
the anatomical point of view, in-depth echocardiogram
examination is required. An anatomical assessment of the
LAAwith computed tomography or magnetic resonance can
be useful if echocardiography is not definitive.
Echocardiogram assessment and
echocardiogram anatomy of the left atrial
appendage
TEE is the method of choice for the anatomical and func-
tional assessment of the LAA. Three-dimensional echocar-
diography may be useful although not essential for a
correct assessment.
When assessing thrombotic risk, it is important to consider
both anatomical and functional aspects in order to assign a
specific LAA-related risk within the overall cardiac and sys-
temic thrombotic risk. As already described, the LAA often
has several lobes and its contractility is themain determinant
of its blood outflow.69 In the context of AF, it has been shown
that a LAA outflow rate> 40cm/s is correlated, after cardio-
version of the arrhythmia, with a reduction in spontaneous
echo contrast.70 A high level of spontaneous echo contrast
correlates with endo-LAA flow rates< 40cm/s and the for-
mation of sludge in the LAA (a pre-thrombotic condition).
The main data on the linear average measurements relat-
ing to this anatomical structure are derived from autopsy in-
vestigations, which have also revealed a correlation with
age and gender. More recently, a study of LAA volumes has
been conducted using multilayer computer tomography,
reaching the conclusion that there are no gender-related
differences although there are differences linked to age-
band (larger at 60–70 years than at 40–59 years).71,72 TEE
allows calculation of the main planimetric parameters
(transverse and longitudinal dimensions and area) which
allow correct planning of the occlusion procedure (Table 6).
‘Step by step’ procedure
There are now a large number of publications which offer a
detailed description of the LAAO procedure.45 Below, we
list some suggestions to be considered useful for standard-
ising the procedure as far as possible, in order to render
outcomes reproducible and reduce complications.
Choice of anaesthesia
Although the procedure can be performed both under gen-
eral anaesthesia and in analgosedation, the former option
appears to be advisable. On the one hand, the need for
transoesophageal monitoring requires prolonged collabor-
ation from patients, who often have difficulty in tolerating
the presence of the oesophageal probe. On the other hand,
Figure 8 Algorithm for stroke prevention in patients with atrial ﬁbrillation. CRF, chronic renal failure; NOACs, new oral anticoagulants, OAT, oral anti-
coagulant therapy. Adapted from Meier et al.44
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general anaesthesia allows the patient’s complete immo-
bility to be guaranteed, preventing small, involuntary
movements which may increase the risk of mechanical
complications, especially during the transseptal puncture
or during manipulation of the deployment system inside
the LAA. Although the possibility of performing the proced-
ure under local anaesthetic with intracardiac echocardio-
graphic guidance is intriguing, sufficient data are not
available for this approach to be recommended. In fact, al-
though transseptal puncture under intracardiac echocardi-
ography is feasible, it currently appears difficult to
establish the size of the device and assess its positioning
without the use of TEE.
Choice of vascular access
The access of choice is the right femoral vein, which simpli-
fies the manipulation of the materials and gives more safer
transseptal puncture; the literature describes performance
of the procedure through a puncture in the left femoral
vein,73 but this access should only be used in patients
where the right access is impracticable (severely twisted
vessel, previous vascular access, large arteriovenous fis-
tula, etc.). Here again, in-depth knowledge of the mater-
ials and specific experience in the management of the
possible vascular complications are important.
Transseptal puncture
This is one of the most delicate phases of the procedure.
Although for a skilled electrophysiologist or haemo-
dynamics specialist performance of the transseptal punc-
ture with fluoroscopic monitoring only (with or without
aids such as a coronary catheter) is not a specific problem,
the use of echocardiographic guidance for the puncture is
strongly recommended in order to obtain a better angle of
approach to the LAA. A puncture low down to the rear ex-
poses the LAA with the ideal angle for existing deployment
systems (Figure 9). Passage of the interatrial septum
through the patency of the foramen ovale offers an angle
which is less than ideal, which may render the subsequent
proceduremore problematical and less safe.
Intraprocedural antithrombotic therapy
Although the literature describes cases of LAAO performed
during therapy with warfarin in the therapeutic range, in
order tominimize the risks all anticoagulant therapy should
have been suspended at least 48 h prior to the procedure,
and the INR value should be< 2. Once the transseptal
puncture has been performed, antithrombotic therapy
must be administered: non fractionated heparin (dosage
70–100U/kg to obtain an activated coagulation time of
250–300 s) is the first choice. In our opinion, the dwell time
in the left atrium should be minimized in order to reduce
the risk of embolism. In the event that the TEE reveals
thrombosis on the deployment system, we advise manual
aspiration of the thrombus through the catheter, associ-
ated with the administration of heparin; if this strategy
fails, the procedure should be interrupted.
Insertion of the deployment system into the left
atrium
There are two possible approaches:
a. the deployment system delivery catheter is exchanged
over a stiff guidewire which is placed in the left upper
pulmonary vein and then manoeuvred, containing a pig-
tail catheter through which the angiography of the LAA
will also be performed. If this approach is chosen when
using the ACP-Amulet system, a longer pigtail catheter
(125cm) will be needed. It should be emphasized that
with this procedure the system can be manoeuvred
with greater safety and the risk of iatrogenic damage
when the delivery catheter is moved into the LAA is
reduced and
b. the alternative method is to use the pigtail for the
angiography and then exchange it for the deployment
system delivery catheter on a rigid guide positioned
in the LAA (this ‘saves’ one exchange but increases
the risks of tearing of the wall of the LAA).
Table 5 Screening factors
Thromboembolic risk score
Haemorrhage risk score
Age
Patient’s preference and health expectations
Diagnosis of diabetes mellitus
Arterial pressure assessment
Kidney function assessment
Cardiac function assessment, NYHA class
Carotid and/or aortic vascular assessment
Liver and gastrointestinal diseases (angiodysplasia, peptic
ulcer)
Assessment of coagulative factor and haemorrhagic diathesis
Assessment of contraindications for coagulants
Assessment of multi-drug interaction
Assessment of therapeutic compliance and frailty
Assessment of psychiatric diseases (dementia, alcoholism)
Colour-Doppler transthoracic echocardiogram
Colour-Doppler transoesophageal echocardiogram
Cardiac angio-CTor angio-MR
CT, computed tomography; MR, magnetic resonance; NYHA, New
York Heart Association.
Table 6 Main echocardiographic parameters to be obtained
Dimensions of LAA and atrium
Shape of LAA
Flow rates within LAA
Relations with mitral isthmus and annulus
Presence/absence of structural defects of the atrium (patent
foramen ovale, interatrial septum aneurysm, atrial or LAA
thrombosis, spontaneous echo contrast)
Left ventricle functions and dimensions
Mitral valve function
Presence/absence of pericardial effusion
LAA, left atrial appendage.
D344 G. Casu et al.
Downloaded from https://academic.oup.com/eurheartjsupp/article-abstract/19/suppl_D/D333/3792694
by Uni MIlano user
on 15 December 2017
Choice of device
A number of devices have been developed and placed on
the market. However, in clinical practice the devices cur-
rently available are the Watchman (Boston Scientific) and
the New Amulet (St. Jude). The Lariat device is used for
combined endocardial-epicardial ligature of the LAA and
will not be discussed here. The scientific findings support-
ing the use of the devices were discussed in the previous
section; here, we will simply detail the devices’ specific
technical features. It should be underlined that both the
devices available on the market are completely reposition-
able and recapturable in the event of imperfect deploy-
ment or if the chosen size is not suitable.
TheWatchman device is inserted bymeans of a preformed
deployment system (single or double bend) of 14 Fr. For opti-
mal sealing, it is recommended that the device chosen
should be oversized by 10–20% (it is available in sizes from 21
to 33mm). A higher device oversizing percentage appears to
offer better leak reduction but could bemore risky. The new
generation of the device, which will probably be on themar-
ket from 2016, will provide better sealing even without
oversizing, thanks to an increase in the number of anchor
hooks and a shallower profile. For the current generation of
the device, the depth of the LAA must be similar to the
diameter to allow safe deployment. In the Panel’s experi-
ence this characteristic, which is apparently the device’s
biggest drawback, has never prevented safe implantation,
probably because several studies74 have shown that as AF
persists, LAA increase in size, generally with the same rate
of expansion in their diameter and depth. However, if in
doubt it is important to use the radiopaque markers pro-
vided on the deployment system which easily reveal the
minimum device deployment depth.
The New Amulet occlusion device (the evolution of the
Amplatzer ACP system, now more or less replaced on the
market by the New Amulet) has an unusual structure which
enables it to adapt to virtually any LAA morphology. This
device is able to occlude all LAAs between 11 and 31mm
and is inserted in a deployment system with 9–14 Fr deliv-
ery catheters (depending on the size of the device). It
should be remembered that while the delivery catheters of
the ACP were available in diameters 9, 10, and 13 Fr, those
of the Amulet are in sizes 12 or 14 Fr.
Preparation of the system and device
After the device and size have been chosen, the implant-
ation system and device must be prepared. Experience has
shown that through flushing of the catheter and device is
essential to minimize the risk of air embolization during
implantation.
Implantation of the device
Once the deployment system is in an appropriate positon,
it is withdrawn, enabling the device to open. In this phase,
small movements are sometimes required to adjust the de-
vice’s positon, turning, pushing, or pulling to correct the
angle of access to the LAA, which is not always optimal in
spite of careful planning of the transseptal puncture. Once
the device is open, a combined check is performed by angi-
ography (the electrical projections are the right cranial
and right caudal arteries) and echocardiography, to check
stability (shape and compression) and efficacy (presence of
leaks). This is followed by a tug test on the deployment
wire.
Figure 9 View of the fossa ovalis and the preferred points for the puncture for LAA occlusion. ACP, Amplatzer Cardiac Plug; AF, atrial ﬁbrillation; Ao,
aorta; LA, left atrium; LAA, left atrial appendage; LV, left ventricle; RA, right atrium; RV, right ventricle.
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Deployment of the device
Once the result is considered satisfactory, the device can
be deployed by turning the deploymentwire anticlockwise.
At the end of the procedure, an additional echocardio-
graphic check is required to ensure that the device is cor-
rectly positioned and that there are no pericardial
effusions (which may occur at any phase of the implant-
ation process). The system is then removed and local
haemostasis is performed (manual compression or figure-
of-8 suture). The decision as to whether to administer
protamine sulphate will depend on the assessment of its
clinical utility as appropriate to the individual patient.
Management of antithrombotic therapy after
the procedure
After the procedure, antithrombotic therapy is recom-
mended to prevent the formation of thrombi on the device
until its complete endothelialization. The current manage-
ment protocol is the outcome of the PROTECT AF,48
PREVAIL,51 and ASAP52 studies based on the Watchman de-
vice and experience gained from use of the Amplatzer PFO
Occluder device.
For the Watchman device, the antithrombotic protocol
of the PROTECTAF trial involved the suspension of warfarin
45 days after the procedure and its replacement with dual
antiplatelet therapy if the TEE revealed the absence of
thrombi or a residual leak< 5mm; the second antiplatelet
medication was suspended after 6 months if the follow-up
TEE did not show significant periprosthetic leaks around
the device. The PREVAIL trial and the ASAP study revealed
the feasibility of DAPT as an alternative to therapy with
warfarin after implantation of theWatchman device.
Observational studies assessed DAPT for 1 month after
implantation of the ACP device and single antiplatelet
therapy for the next 3–6 months, in accordance with the
antithrombotic therapy protocol acquired from experience
with the Amplatzer PFO Occluder.75
In all these various therapeutic approaches, single anti-
platelet therapy is indicated quoad vitam.
DAPTwith aspirin and clopidogrel can be suggested with
the execution of TEE at 3 months or even earlier in the
event of significant post-procedural leaks (5mm). If
there are no complications of any kind, the second antipla-
telet therapy could be suspended after this period and an
echocardiogram (by the transoesophageal approach) re-
peated after about 1 year. However, widely varying proto-
cols are found in the records of the largest centres for
patients with high and very high risk of haemorrhage, with
the use of low molecular weight heparin therapy for a
period ranging from a few days to some weeks, the use of a
single antiplatelet therapy or, in specific cases, no antith-
rombotic therapy.
The incomplete occlusion of the LAA is another topic open
to discussion. In theory, this could create pockets, which
would be a potential source of cardioembolism. However,
small residual leaks (<5mm) are considered irrelevant and
may close spontaneously; their presence has not been
shown to imply an increased risk of thromboembolism com-
pared to patients with complete LAAO76 although their
clinical significance requires assessment in large
randomized prospective studies with longer term follow-up.
Recommended organisational and operating
standards
The expansion of the LAAO procedure within intervention-
ist cardiology has led both national77 and international48,67
scientific societies to put forward recommendations and
propose operating standards for the centres intending to
adopt it. Some requirements should be considered essen-
tial; those listed below are the requirements to be con-
sidered fundamental for centres and staff.
General requirements
Within the hospital, the LAAO procedure should include
joint decision-making within the Heart Team, including the
interventionist cardiologist (haemodynamic specialist or
electrophysiologist), the clinical cardiologist, the echocar-
diographer, the anaesthetist, and the cardiac surgeon, to
ensure optimal coordination of the procedure. Since pa-
tient selection is the first fundamental step, other special-
ists (neurologists, nephrologists, internists, geriatrists, and
haematologists) may be involved in indicating LAAO as the
most appropriate antithrombotic strategy for a given pa-
tient. Therefore, the formation of a multidisciplinary team
should be a prerequisite for the choice of the ideal candi-
date, the success of the procedure and post-procedural
management. The presence/availability of a cardiac sur-
gery unit on site is considered as a requirement in the
North American Heart Society document67 and is also rec-
ommended by the recent EHRA/EAPCI guidelines44 which
consider access to a cardiac surgery theatre within 60min.
adequate. The joint document issued by the Societa
Italiana di Cardiologia Interventistica/Associazione Italiana
di Aritmologia e Cardiostimolazione (GISE/AIAC) requires
the presence of a cardiac surgery unit on-site.77
Staff training and preparation
Interventionist cardiologists or electrophysiologists intend-
ing to perform the LAAO procedure must have in-depth
knowledge of the anatomy of the heart, and of the morpho-
logical characteristics of the atrium and the LAA in particu-
lar. All scientific societies underline the need for the
professional performing the procedure to have specific ex-
pertise in transseptal puncture and how to perform it in re-
lation to implementation of LAAO devices. With regards to
the transseptal puncture, the position of the national and
international electrophysiology societies [AIAC/Heart
Rhythm Society (HRS)] is that the professional should have
performed at least 50 transseptal punctures and be skilled
in manoeuvring catheters/inserters in the left atrium. The
professional must be familiar not only with the anatomical
position of the LAA and how to reach it but also the relation-
ships between this structure and the surrounding anatomical
formations. He or she must also have sufficient experience
in the interpretation of radiological images (from angiog-
raphy, tomography and magnetic resonance) and echocar-
diogram images of the LAA to obtain all the information
needed for the correct choice of device. In particular, the
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scientific societies emphasize the need for consultation be-
tween the professional performing the procedure and the
echocardiographer, a key factor for success.
Professional performing the procedure must also have
experience in pericardial puncture (or at least an interven-
tionist cardiologist with this technical skill must be pre-
sent) in order to deal with the eventuality of pericardial
tamponade during manoeuvres in the left atrium or pos-
itioning of the device in the LAA.
Training of the first professional in the skills needed to
perform the procedure is the fundamental first step in
becoming autonomous. Training is provided by a proctor
who is able to supply the trainee with explanations of all
the phases of the procedure for successful LAAO. In detail,
the recommendations of all the various scientific societies
agree that every professional must attend theoretical les-
sons together with technical support through familiar-
ization with the procedure and the instruments required,
involving virtual sessions using simulators and/or practical
sessions, in animal laboratories where possible.
It is advisable for those who are learning the procedure
to attend implantation operations in order to learn the
various steps with precision. The proctor must be present
at the first implantation performed in every centre.
Although there is no minimum number required to allow a
professional to acquire complete independence, it is rea-
sonable to assume that at least 15 implants must be per-
formed in each centre before a satisfactory degree of
autonomy and independence is gained.
One key factor for the achievement of procedural suc-
cess, strongly recommended in the documents of the vari-
ous scientific societies, is the creation of a well-organized
operating team including the echocardiographer, the an-
aesthetist, and the nursing staff, who must also be familiar
with the characteristics of the various devices and have
proven experience in interventionist cardiology/electro-
physiology procedures.
Requirements for the centre and operating room
Since most procedures are performed under general anaes-
thetic, the operating room must have the instrumentation
required for anaesthesiology and have sufficient physical
space not only for the anaesthetist but also for the echo-
cardiographer, who plays a fundamental role in the proced-
ure. The international scientific societies require the
operating room staff, including nursing and technical staff,
to have experience in interventionist procedures and be
able to understand every step of the procedure, such as,
for example, how to respond quickly to emergencies.
Staff’s familiarity with thematerials used is an additional
factor in facilitating all steps of the procedure. Although
not specifically recommended by the various scientific
societies, it would be preferable for the nursing members
of the team also to be involved in the technical training, at-
tending LAAO sessions performed by the proctor and get-
ting to know thematerials by means of virtual sessions.
All operating room staff involved in the procedure must
have a clearly defined role to play, in order to prevent
overlaps during the procedure and delays in responding to
emergencies.
Procedural recommendations and minimum skill
levels
In view of the large number of procedures already per-
formed and the potential additional increase in the near
future, it appears appropriate for the national and scien-
tific societies to draw up a position which can act as a con-
sensus guideline. Therefore, on the one hand, the existing
literature has been combined to extract indications for the
selection and preparation of patients for the procedure.
On the other hand, considering the opinions of staff skilled
in the procedure, it appears useful to analyse the most
purely technical aspects of percutaneous LAAO in order to
standardize the various steps of the method, increasing its
success in acute cases and reducing complications.
Requirements for the facility and staff
As already stated, percutaneous LAAO is a procedure which
requires a multidisciplinary approach and can be per-
formed either by an electrophysiologist or by a haemo-
dynamic specialist: professionals from both these
disciplines can combine their specific skills. However, the
general opinion is that this procedure is technically com-
plex and is a considerable challenge within interventionist-
structural cardiology, due to the large number of skills
required (transseptal puncture, navigation in left atrium
and LAA, use of contrast medium, catheters and specific
materials) (Figure 10).
Therefore, this working group believes that a facility
wishing to start a percutaneous LAAO programme must
have a multidisciplinary team allowing optimal assessment
of the patient for the procedure. Particular attention will
be focused on cardiac imaging techniques, in order to as-
sess feasibility and plan the procedure most effectively:
the presence of a specialist echocardiographer, both to
monitor the positioning of the device and to recognize
acute complications, is fundamental (Table 7).
Although it is not a sine qua non, radiological imaging
plays a major role: high definition multidetector computed
tomography and cardiac magnetic resonance are able to
identify any thrombotic formations and study the anatomy
of the LAA most effectively.78 However, it must be under-
lined that these techniques are not the ideal support during
the procedure, although they are useful, especially during
the initial phases.
It thus appears advisable to perform the entire proced-
ure under the guidance of echocardiography and fluoros-
copy, as already emphasized in the PROTECTAF study. In all
cases, according to the data in the literature and the ex-
perience of many professionals, it does not seem to be
more risky than other interventionist procedures such as
transcatheter ablation of AF, with which it shares the risk
of mechanical complications (cardiac tamponade and dam-
age to the structures adjoining the left atrium). It is im-
portant to point out that the incidence of what is to all
effects the most serious complication, cardiac tamponade,
has fallen over the years as operators’ experience has
increased and the technical characteristics of devices have
improved: the rate has decreased from the about 5% of
PROTECT AF48 to a minimum of 0.8–1.3% in the latest ‘real
world’ registry studies.51,58 Analysing the data available to
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us from the PROTECTAF48 and PREVAIL51 studies, which to-
gether total 1271 patients, we find 40 (3.1%) pericardial ef-
fusions; the two studies report that 10 (0.8%) of these were
surgically drained within 7 days after deployment of the
device. If we compare the data of the two studies,
PROTECTAF and PREVAIL, there is a significant reduction in
surgically drained pericardial effusions (P¼ 0.027), with a
fall from 1.6% to 0.4%.
Considering the complexity of the procedure and the po-
tential complications, with current knowledge and the
data now available, the need for a cardiac surgery team
on-site has been the subject of debate, as reflected by the
different positons taken in the international documents.
Although the majority of the Panel believed that the pres-
ence of a cardiac surgery team on-site was not an indis-
pensable requirement and that access to a cardiac surgery
room within 60min. was sufficient a unanimous position on
this point was not achieved, even after lengthy discussion.
One essential prerequisite (relevant for both intervention-
ist cardiologists and electrophysiologists) is skill in
pericardiocentesis.79
Management of complications
Pericardial effusion and cardiac tamponade
Pericardial effusion, in all its clinical forms (from asymp-
tomatic effusion to cardiac tamponade) is one of the most
serious complications of the percutaneous LAAO proced-
ure. The risk factors include the transseptal puncture, the
manipulation of rigid structures like the delivery catheters
and the devices themselves inside the left atrium, and the
intrinsic fragility of the atrial wall.80
In the PROTECT AF study, conducted on the Watchman
device, the incidence of pericardial effusion within 7 days
of implantation was 4.4%, with pericardiocentesis required
in 3.3% of patients.48
It should be underlined that this complication was
observed more frequently at the start of the learning
curve. In the registry of the PAC system, which contains the
results achieved by skilled staff, the rate of pericardial ef-
fusion fell to 2.2%74 and the same values were also reported
in the subsequent PREVAIL trial.51 The recent study per-
formed by Tzikas et al.57 on the results achieved with the
ACP device inmore than 20 European and Canadian centres
revealed a rate of pericardial effusion requiring drainage
of 1.2%. In a multicentric study analysing the data on the
use of the Lariat device, Price et al.81 report an incidence
of pericardial effusion requiring drainage of 10.4%.
The procedural strategies to reduce the incidence of
pericardial effusion include:
• performance of the device implantation procedure
under TEE guidance and pressure monitoring to ensure
safe transseptal puncture in the correct position;
• use of a pigtail catheter inside the access sheath or a
loop wire in the LAA to facilitate safe, trauma-free
movement inside it;
• the use of slow, careful movements during manipula-
tion of the catheter and occlusion device inside the
left atrium; and
Figure 10 Complexity ratio between the procedures used in interventionist cardiology. ASD, atrial septal defect; PFO, patent foramen ovale; TAVI,
transcatheter aortic valve implantation.
Table 7. Intraprocedural complications which can be iden-
tiﬁed by echocardiography.
1. Pericardial effusion
2. Cardiac tamponade
3. Embolization of the device
4. Thrombosis on the catheter
5. Tearing of the left atrial appendage
6. Damage to nearby structures:
7. During transseptal puncture
8. During manipulation or deployment of the device
9. Interference with the mitral valve, the circumﬂex artery
or the left upper pulmonary vein
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• performance of the tug test after implantation of the
device under echocardiographic and fluoroscopic guid-
ance, with injection of small amounts of contrast
medium.
With regards to the therapeutic management of pericar-
dial effusion, in the case of cardiac tamponade with hypo-
tension a swift, aggressive approach is required, with
pericardiocentesis and suspension of anticoagulation ther-
apy. Early diagnosis of a pericardial effusion by means of
TEE/intracardiac echography can often prevent the onset
of cardiac tamponade, leading to serious deterioration of
the haemodynamic condition.
Pericardiocentesis can be performed by means of a sub-
xiphoid or subcostal transcutaneous puncture with echo-
cardiographic guidance, or through a small cutaneous
incision of about 3–5 cm underneath the xiphoid appendix
(subxiphoid window), which allows the pericardial cavity
to be accessed directly through its incision, followed by in-
sertion of a pericardial drain.
In the event of recurrent tamponade or perforation of
the left atrial wall, conventional surgery is required to re-
view the pericardial cavity, suturing the breach in the atrial
wall in an off-pump, beating heart procedure (if possible).
If the lesion requires luxation of the heart for better surgi-
cal exposure, and tolerance of this procedure is poor,
extracorporeal circulation may be necessary.
In selected cases, a thoracoscopic approach may initially
be indicated, with fitting of an epicardial device (e.g.
AtriClip) to close the breach in the LAA, if the lesion does
not involve its orifice. This technique has not yet been
described in the literature, and where it is not indicated
the thoracoscopic approach can be transformed into mini-
thoracotomy, which allows easier control of the anatomical
structures and control of the haemostasis.
Although most cases of pericardial effusion occur early,
subacute forms and delayed effusions are still described in
the literature after the implantation of percutaneous LAAO
devices. Therefore, monitoring of heart rate and arterial
pressure are recommended for at least 48 h after implant-
ation of the device, with performance of a transthoracic
echocardiogram before discharge to ensure that no pericar-
dial effusion has occurred and that the device is correctly
positioned. Subacute effusions may be due to rubbing or
irritation caused by the device’s anchors against the wall of
the atrium, in which lesions may eventually occur in view
of its thinness. In these cases, if the pericardial effusion
is of significant extent or produces instrumental signs
of haemodynamic impairment, pericardiocentesis, or in
some cases conventional surgical exploration, must be
performed.
Delayed, haemodynamically insignificant effusions can
probably be ascribed to post-procedural inflammation.
They are normally treated with non-steroid anti-inflamma-
tories such as aspirin, ibuprofen and diclofenac, or more
rarely with steroid therapy.
Gaseous embolism
Gaseous embolism is often a clinically silent event, al-
though in rare cases it may cause TIA, acute coronary is-
chaemia, hypotension and/or cardiac arrest.48 Gaseous
embolisms may reach the left atrium due to an accidental
injection of air or may be the consequence of gas bubbles
generated by a gradient between atmospheric and intra-
cardiac pressure due to a deep intake of breath.82
Most of the management of gaseous embolisms consists
of support. Hyperbaric oxygen has shown clinical benefits
in 80% of cases of cerebral gaseous embolism, although no
controlled studies have yet been performed. Gaseous em-
bolism in the coronary circulation most often becomes evi-
dent in the right coronary due to the anatomical position of
its orifice, and is often resolved within a few minutes.
However, it may generate an ST depression, hypotension
and ventricular arrhythmias, through to cardiogenic shock.
Aspiration of the air with a specific device or the injection
of contrast medium into the coronary artery may be useful
in these cases.
Embolization of the device
The implantation procedure may be complicated by imme-
diate or delayed formation of embolisms around the perim-
eter of the device itself. The careful selection of patients
with favourable LAAmorphology and use of the appropriate
size of device are crucial for preventing this complication.
Conversely, negative predictors are:
• large LAA orifice size,
• use of undersized devices,
• short LAA, and
• unusual anatomical variants.
Embolized devices in the left atrium or left ventricle can
be captured and then driven forwards towards the mitral
and aortic valves by means of endocatheters, allowing
them to be recovered in the descending aorta. The recov-
ery of devices from inside the heart itself is difficult and
dangerous, while recovery in the aorta with a loop or bio-
ptome catheter is a safer, more reproducible method. In
the rare cases of the embolization of larger-sized devices
in the direction of the iliac-femoral axis, recovery through
open surgery is necessary.
Conclusions
OAT is the strategy of first choice for the prevention of
thromboembolic events in AF patients with medium/high
risk (CHA2DS2-VASc1). However, many of these patients
are difficult to treat, especially due to bleeding, a danger-
ous adverse event related to the therapy, which limits or
contraindicates its use. The observation that most thrombi
are generated by the LAA has led to the consideration of its
surgical or percutaneous occlusion as an alternative; during
the last few years, the Watchman percutaneous occlusion
device has proved to be not inferior to anticoagulant ther-
apy for the prevention of thromboembolic events, with the
added benefit of a lower rate of haemorrhagic events;
other, new devices have recently been introduced or are
under development.
The procedure for the percutaneous occlusion of the LAA
requires considerable technical skill and theoretical know-
ledge, as well as suitable training under the supervision of
expert colleagues. Anyone wishing to perform it will
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require the cooperation of skilled echocardiographers, fa-
miliar with the transoesophageal technique, to obtain the
support of suitable imaging; he or she must also be capable
of managing any complications, meaning, in particular, ex-
perience in the execution of pericardiocentesis, since car-
diac tamponade is the most common and most dangerous
complication.
The presence of a cardiac surgery unit on-site does not
appear to be indispensable although it is reasonable to en-
sure access to a cardiac surgery room within 60min. if
necessary.
At present, the main indication for LAAO is the relative
or absolute contraindication of anticoagulant therapy in
patients with AF. These indications derive from observa-
tional or registry studies made comparing devices with the
use of warfarin. Fur the future, the indication for LAAO in
association with the AF ablation procedure AF83–85 and
MitraClip implantation, and the data obtained from com-
parison with the NOACs, remain to be assessed.
Large populations of very high-risk patients have still not
been studied, including those who are unable to take any
type of anticoagulant or antiplatelet therapy, in order to
establish the impact of these factors on the prevention of
complications andmortality.
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